ArticleTranslational lung cancer research2025
Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer.
Bilal Krayim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.